Core Insights - The report indicates that the 2025 Central Economic Work Conference is more focused on "structural adjustment," suggesting a potential for a structural market trend in the upcoming year [4][6][26] - Historical patterns show that years emphasizing "stabilizing growth" typically lead to stronger market performance, favoring large-cap stocks over small-cap and value stocks over growth stocks [2][10] - Conversely, years focused on "structural adjustment" tend to exhibit market volatility, with large-cap stocks remaining flat while small-cap stocks weaken [2][10] Summary by Sections Historical Performance Post-Central Economic Work Conference - The report categorizes past conferences into two themes: "stabilizing growth" and "structural adjustment," with specific years identified for each theme [1][2] - Years with a "stabilizing growth" focus include 2014, 2018, 2019, 2021, 2022, and 2024, characterized by economic slowdowns and policies aimed at maintaining stability [1][2] - Years emphasizing "structural adjustment" include 2013, 2015, 2016, 2017, 2020, and 2023, where the focus was on addressing structural issues and risks [2] Market Behavior and Style Preferences - In "stabilizing growth" years, the market index typically strengthens, with large-cap stocks outperforming small-cap stocks and value stocks outperforming growth stocks [2][10] - In "structural adjustment" years, the market tends to be more volatile, with large-cap stocks showing flat performance and small-cap stocks declining [2][10] Industry Performance Insights - The report notes that the focus of the Central Economic Work Conference influences the following year's market trends, with specific industry policies guiding investment directions [3][4] - For instance, the emphasis on "innovation-driven" policies in 2012 led to a TMT boom in 2013, while the focus on "new consumption" and "new infrastructure" in 2018 shaped market trends in 2019 [3] 2025 Conference Insights - The 2025 conference highlights a "supply strong, demand weak" scenario, indicating a need to balance supply and demand dynamics [4][6] - The report suggests that monetary policy will prioritize economic stability and reasonable price recovery, which could lead to improved corporate profitability if inflation expectations rise [6] - Expanding domestic demand is a key focus, with policies aimed at increasing consumer income and stabilizing investment to counteract previous declines in fixed asset investment growth [6] Market Outlook and Sector Allocation - The report anticipates a structural market trend in 2025, with specific sectors recommended for investment, including AI applications, semiconductor, and renewable energy sectors [7] - The report emphasizes the importance of monitoring macroeconomic conditions and policy developments to inform investment strategies in the upcoming year [7]

Market Overview - The overall sentiment in the pharmaceutical sector remains cautious, with the CITIC Pharmaceutical Index declining by 1.10%, underperforming the CSI 300 Index by 1.02 percentage points, ranking 15th among 30 primary sectors [9] - The retail scale of physical pharmacies in China for the first three quarters of 2025 reached CNY 449 billion, a year-on-year decline of 1.9%, with Q3 showing a cumulative scale of CNY 152.9 billion, down 1.4% year-on-year but up 3.0% quarter-on-quarter [21][15] Drug Market Analysis - The drug retail market in Q3 experienced a slight year-on-year decline, attributed to factors such as reduced incidence of respiratory diseases. The cumulative scale for the first three quarters was CNY 3,654 billion, down 0.8% year-on-year, with Q3 retail scale at CNY 1,241 billion, also down 0.8% year-on-year [28][23] - The sales growth rate for major drug categories showed a downward trend, with the largest decline seen in health products, exceeding 17%, while the smallest decline was in pharmaceuticals, slightly down by 1.2% [22] Traditional Chinese Medicine (TCM) Analysis - The cumulative scale of TCM retail in physical pharmacies for the first three quarters of 2025 was CNY 344 billion, down 4.4% year-on-year, with Q3 cumulative scale at CNY 117 billion, down 4.1% year-on-year [25] - Monthly retail scale for TCM showed fluctuations, with September seeing a significant month-on-month increase of 9.8%, indicating potential recovery [25] Medical Device Market Analysis - The medical device market showed signs of recovery in Q3, with a cumulative scale of CNY 210 billion for the first three quarters, down 1.9% year-on-year, and Q3 cumulative scale at CNY 73 billion, remaining stable year-on-year [35][29] - The market for high-value consumables, particularly in orthopedics, is expected to grow due to increased surgical volumes and domestic market consolidation following procurement policies [46] Health Products Market Analysis - The cumulative scale of health products in physical pharmacies for the first three quarters was CNY 171 billion, down 17.0% year-on-year, with Q3 cumulative scale at CNY 57 billion, down 13.6% year-on-year [32] - Monthly retail scale for health products showed a recovery trend in September, with a month-on-month increase of 22.2%, indicating a narrowing of the year-on-year decline [32] Investment Opportunities - The pharmaceutical sector is viewed as having low valuations, with public funds showing low allocation to the sector. The anticipated recovery in macroeconomic factors and the potential for significant growth in large categories are seen as positive indicators for the industry [13] - The innovation drug sector is expected to shift focus from quantity to quality, emphasizing differentiated products and internationalization, with recommendations to focus on companies that can deliver profits [13]

Core Viewpoint - The company, Shouyao Holdings (688197), is planning to issue overseas shares (H-shares) and list on the Hong Kong Stock Exchange to enhance its core competitiveness and brand influence, while optimizing its capital structure and diversifying financing channels [1] Group 1 - The company is currently in discussions with intermediaries regarding the specific progress of the H-share listing [1] - The details of the H-share listing have not yet been finalized [1] - The H-share listing will not result in any changes to the company's controlling shareholder or actual controller [1]

Core Viewpoint - Maiwei Biotech, a company listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in 2022, has grown into a billion-dollar enterprise with 15 key products in various stages of clinical development and a research team of nearly 400 people [1] Group 1: Company Overview - Maiwei Biotech has developed two first-in-class drugs, positioning itself among the top tier of the global biopharmaceutical industry [1] - The company has not yet achieved profitability but has effectively addressed critical pain points in research and development [1] Group 2: Industry Context - A total of 22 biopharmaceutical companies, including Maiwei Biotech, have adopted the fifth set of listing standards on the Sci-Tech Innovation Board, with cumulative R&D investments exceeding 70 billion yuan over the past three years [1] - The Sci-Tech Innovation Board is facilitating significant R&D investments from innovative drug companies, which are substantially higher than the average level in the sector [1] - Through institutional innovation, capital injection, and supportive measures, the Sci-Tech Innovation Board is helping biopharmaceutical companies overcome challenges related to long R&D cycles, high investment costs, and slow profitability, enabling a leap from R&D to commercialization and from local to global markets [1]

Group 1 - A-shares showed a rebound after hitting a low, with significant support at lower levels, as most sectors rose, particularly semiconductor equipment and electric grid technology sectors [1] - The Shanghai Composite Index closed at 3889.35 points, up 0.41%, while the Shenzhen Component Index rose by 0.84% and the ChiNext Index increased by 0.97% [1] - Market sentiment improved with a trading volume of approximately 2.1 trillion yuan, an increase of over 200 billion yuan compared to the previous day, indicating a recovery in trading activity [1] Group 2 - The market is expected to continue its upward momentum, supported by policies from the Central Economic Work Conference addressing concerns in consumption, investment, and technology [2] - Economic data, while exerting short-term pressure, may create long-term expectations for recovery, suggesting that the market will stabilize as the real economy improves [2] - A flexible investment strategy combining core positions with satellite rotation is recommended to navigate the current market volatility, with a focus on capturing long-term investment opportunities in the Chinese economy [2] Group 3 - The Hang Seng and Hang Seng Tech indices both closed higher, showing stronger performance compared to A-shares [3] - U.S. stock indices continued to rebound, with the Dow Jones Industrial Average reaching a historical high, while the S&P 500 index is close to recovering its previous losses [3] - Investor sentiment in the tech sector is shifting, as there is a growing fatigue with AI narratives, leading to a search for companies with more certain earnings support [3]

注：恒生指数的本周表现 值得注意的是，本周港股市场呈现V型走势。周三恒生指数一度急跌逾3%，科技指数同步下探近3%，市场情绪一度转冷；但随后两个交易日，两大指数均 逐级反弹，并收复部分跌幅。 市场研判：短期反弹与中期震荡并存 恒生指数与科技指数本周展现的V型走势，有力印证了机构对港股"短期波动与中期修复并存"的前瞻性判断。 震荡格局中的结构性机会 机构普遍认为，当前港股市场正处于复杂的结构性行情中。 中金公司最新研报指出，市场目前处于"青黄不接"的震荡阶段，缺乏明确的单边突破方向，预计在2026年基准情境下，整体仍将维持震荡格局。 中信证券在其最新策略报告中特别强调，当前互联网巨头企业估值水平与其基本面存在明显背离，投资者可重点关注两类机会：一是传统业务随宏观经济企 稳带来的估值修复；二是AI等创新业务驱动的长期价值重估，尤其是已实现商业化落地的AI应用场景。 个股亮点：长飞光纤光缆领衔涨幅榜 本周个股表现中，长飞光纤光缆(06869.HK)、圣诺医药-B(02257.HK)、东方电气(01072.HK)涨幅居前。 长飞光纤光缆以超34%的累计涨幅领跑市场。该股走强主要受益于国家发改委等部门近期推动新型基础设 ...

Investment Rating - The report maintains a positive outlook on the overseas pharmaceutical sector, particularly highlighting the recent developments in drug approvals and partnerships [1][5]. Core Insights - The 2025 National Medical Insurance Directory and the first version of the commercial health insurance innovative drug directory were released, adding 114 new drugs, including 111 new drugs approved within the last five years. The success rate for negotiations was 88.19% [1][6]. - Fosun Pharma's subsidiary has licensed an oral GLP-1 drug to Pfizer, with potential milestone payments totaling up to $15.85 billion [2][7]. - The report emphasizes the importance of ongoing clinical trials and the introduction of innovative drugs in the market, which are expected to drive growth in the pharmaceutical sector [10]. Summary by Sections Domestic Policy Developments - The 2025 National Medical Insurance Directory includes 114 new drugs, with 112 successfully negotiated from 127 that entered the bidding process. Most renewal drugs were renewed at original prices, with an average price reduction of 8.4% for 15 drugs [6][7]. Domestic Pharmaceutical Company Updates - Fosun Pharma's subsidiary has signed a licensing agreement with Pfizer for the global development and commercialization of an oral GLP-1R agonist, with an upfront payment of $150 million and potential milestone payments [2][7]. - The approval of clinical trials for HER2 monoclonal antibodies for breast cancer treatment has been granted, indicating progress in innovative cancer therapies [2][7]. - New clinical data for a BCL2 inhibitor was presented, showing promising efficacy and safety in treating various blood cancers [2][7]. Overseas Pharmaceutical Company Updates - Wave Life Sciences reported positive Phase I data for an siRNA drug targeting obesity, showing significant reductions in visceral fat and overall body fat [3][9]. - Structure Therapeutics announced positive results for its oral GLP-1 small molecule, demonstrating substantial weight loss in clinical trials [3][9]. - Roche received EU approval for a CD20 monoclonal antibody for treating lupus nephritis, marking a significant advancement in autoimmune disease therapies [3][9]. Investment Recommendations - The report suggests focusing on innovative drugs and companies with active business development opportunities, particularly those with promising clinical pipelines [10].

Group 1 - The Hong Kong innovative drug sector is experiencing a rebound, with the Hang Seng Innovative Drug Index rising by 1.3%, potentially ending a four-day decline [1] - Notable stocks in the sector include Kangfang Biotech, which rose over 5%, and other companies like Yimeng Biotech, Cloudtop, and Nuocheng Jianhua, which saw increases of over 3% [1] - The Hang Seng Innovative Drug ETF (159316) recorded a trading volume exceeding 500 million yuan, indicating strong investor interest [1] Group 2 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the implementation of a new "medical insurance directory" and "commercial insurance innovative drug directory" starting January 1, 2026 [1] - The medical insurance directory will add 114 new drugs, including 50 first-class innovative drugs, while the first version of the commercial insurance directory will include 19 drugs, marking a significant advancement in the multi-layered medical insurance system [1] - According to a report by Zhongtai Securities, innovative drugs remain the most important theme in the pharmaceutical sector, with recent price adjustments leading to a more reasonable valuation and increased investment safety margins and return potential [1] Group 3 - The Hang Seng Innovative Drug Index is the first index with a "purity" of 100% focused on innovative drug companies in Hong Kong, and the Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index [1] - This ETF provides investors with a convenient way to capitalize on investment opportunities within the innovative drug sector [1]

中经记者 晏国文 卢志坤 北京报道 "过去，医药投资主要关心药企有没有独家品种、有没有差别定价、销售渠道和能力强不强等。而现 在，医药投资主要关心企业研发管线布局、未来产品出海潜力等。在医改政策的指挥棒下，医药企业核 心竞争力已经发生了巨大的变化。"池陈森说，这个差别背后，核心的推动因素就是国家医药政策的变 化。 池陈森指出，中国有庞大的人口基数，市场需求广阔，有科学家和工程师红利，高校和科研院所众多， 研究效率高，研究成本相对低，中国创新药产业具有很强的优势和巨大的潜力。"就像AI（人工智能） 和人类智能的比拼，一旦AI的能力超过了人类智能，AI的发展是一去不回头的。随着中国创新药企业 在全球竞争中崛起，其未来的发展也会一骑绝尘。" 对于行业未来投资机遇，池陈森认为，近几年国内需求端整体呈现缓慢复苏的态势。局部的、有增量需 求的领域或许可以发现一些好的投资机遇。国内临床上还有很多未被满足的需求，同时创新药企业也应 该将目光瞄准海外，满足海外更广大的市场需求，创新药领域未来会持续有很多投资机会。 池陈森表示，未来，随着中国创新药企业的竞争优势不断增强，在海外市场的经验逐渐丰富，或许可以 在海外市场寻找到更大的 ...

Core Viewpoint - The release of the first commercial insurance innovative drug directory on December 7, 2025, is a focal point for investment discussions in the innovative drug sector, aiming to create new payment channels for high clinical value drugs that exceed basic medical insurance coverage, significantly reducing patient out-of-pocket expenses and enhancing product accessibility and market penetration [1][3]. Group 1: Innovative Drug Directory - The commercial insurance innovative drug directory is designed to open new payment channels for innovative drugs with high clinical value, which are beyond the basic insurance coverage [1][3]. - The directory's implementation is expected to significantly enhance the accessibility and market penetration of innovative drugs, promoting a greater degree of "universal access" [1][3]. - The final selection rate for the directory was approximately 15.7%, highlighting the recognition of differentiated innovative products with significant clinical advantages [1][3]. Group 2: Hang Seng Innovative Drug ETF - The Hang Seng Innovative Drug ETF (520500) is currently the only ETF tracking the Hang Seng Innovative Drug Index, serving as a tool for investors to capitalize on opportunities in the Hong Kong innovative drug sector [1][3]. - As of December 11, 2025, the top five constituents of the index include Kangfang Biotech, China National Pharmaceutical Group, BeiGene, Innovent Biologics, and Kelun-Biotech, reflecting strong R&D capabilities and growth potential [1][3]. - Since December 8, 2025, the ETF has seen a net inflow of 192 million yuan over four consecutive trading days, with its latest share count reaching 1.225 billion and total assets hitting 2.041 billion yuan, both marking new highs since its inception [1][3]. Group 3: Market Outlook - The central economic work conference held on December 10-11, 2025, emphasized "innovation-driven development" as a key task for the upcoming year, aligning with the supportive policy direction for the innovative drug sector [1][3]. - The combination of proactive policy guidance, breakthroughs in payment systems, and maintained liquidity is expected to create a new development opportunity for the Hong Kong innovative drug sector [1][3]. - The high innovation purity of the Hang Seng Innovative Drug ETF (520500) is anticipated to assist investors in seizing the window of opportunity in the Hong Kong innovative drug market [1][3].